Akero Therapeutics AKRO 深 沪
等待开盘 08-21 09:30:00 美东时间
54.65
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 54.65
- 总市值 44.99亿
- 52周最高 58.40
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 21.34
- 委 比 0.00%
- 总股本 8231.62万
- 历史最高 58.40
- 量 比 0
- 振 幅 0.00%
- 历史最低 7.52
- 每 手 1
- 风险率 4.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NextCure To Merge With Avere Therapuetics In All-Stock Deal; NXTC Holders To Receive A Contingent Value Right For 90% Of Net Proceeds From Any Future License, Divestiture Or Monetization Of Its Pipeline Assets And Programs For Two Years; NXTC Also Announces $320M Private Placement
NextCure, Inc. (NASDAQ:NXTC) ("NextCure") and Avere Therapeutics, Inc. ("Avere"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced they have entered into a definitive merger agreement (the "Agreement") for an all-stock transactio...
07-14 18:05
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NextCure and Avere Therapeutics have agreed to merge in an all-stock transaction, with the combined company to operate as Avere Therapeutics, Inc. Avere’s lead program, AVR-001, is a once-weekly oral IL-23 receptor antagonist showing promise in psoriasis. A $320 million private investment will support its development through Phase 2b and Phase 3 trials. The merger is expected to close in 2026, with Avere’s team, including CEO Andrew Cheng, leadin...
07-14 10:00
Cantor Fitzgerald Suspends Overweight Rating on Akero Therapeutics
Cantor Fitzgerald suspends Overweight rating on Akero Therapeutics (NASDAQ:AKRO).
2025-12-10 21:56
Akero Therapeutics Announces Merger and Delisting Plans
Akero Therapeutics ( ($AKRO) ) has provided an update. On December 9, 2025, Ake...
2025-12-09 22:27
Akero Therapeutics Highlights New Data Showing Liver Fibrosis Reversal in MASH Patients
Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced new findings from
2025-11-07 20:07
MNC半年豪掷107亿美元，这个脂肪肝靶点终于爆了
文 | 医曜 早在2023年底的时候，我们就曾推断：脂肪肝将是减肥药后的下一个千亿战场。如今MNC正用真金白银，让这一推断渐渐落地。 10月9日，诺和诺德突然...
2025-10-18 12:37
